Rishi Singh, MD, provides an overview of biosimilars in the context of retinal diseases and discusses their significance within the healthcare system.
Untapped Potential: Exploring Biosimilars for the Treatment of Retinal Diseases
Rishi Singh, MD, presents a case of neovascular age-related macular degeneration and diabetic macular edema demonstrating how the use of ranibizumab biosimilars can yield remarkable anatomical improvements comparable to those expected with reference biologics.
Rishi Singh, MD, discusses the criteria for identifying patients who would benefit from biosimilar therapy.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
ChatGPT-5 overestimates macular hole surgery success, study finds
4
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
5